Adiponectin levels are decreased in mouse models for obesity and type 2 diabetes, whereas administration of adiponectin is considered as a therapeutic treatment strategy for the metabolic syndrome associated with obesity [76,77]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.